JP2008528617A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528617A5
JP2008528617A5 JP2007553278A JP2007553278A JP2008528617A5 JP 2008528617 A5 JP2008528617 A5 JP 2008528617A5 JP 2007553278 A JP2007553278 A JP 2007553278A JP 2007553278 A JP2007553278 A JP 2007553278A JP 2008528617 A5 JP2008528617 A5 JP 2008528617A5
Authority
JP
Japan
Prior art keywords
cancer
subject
composition
patient
multiple myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007553278A
Other languages
English (en)
Japanese (ja)
Other versions
JP5371246B2 (ja
JP2008528617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/002979 external-priority patent/WO2006081445A2/en
Publication of JP2008528617A publication Critical patent/JP2008528617A/ja
Publication of JP2008528617A5 publication Critical patent/JP2008528617A5/ja
Application granted granted Critical
Publication of JP5371246B2 publication Critical patent/JP5371246B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007553278A 2005-01-27 2006-01-27 転移した腫瘍の治療 Expired - Fee Related JP5371246B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US60/647,568 2005-01-27
US66924505P 2005-04-06 2005-04-06
US60/669,245 2005-04-06
US72205305P 2005-09-29 2005-09-29
US60/722,053 2005-09-29
PCT/US2006/002979 WO2006081445A2 (en) 2005-01-27 2006-01-27 Treatment of metastasized tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013129277A Division JP2013177464A (ja) 2005-01-27 2013-06-20 転移した腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2008528617A JP2008528617A (ja) 2008-07-31
JP2008528617A5 true JP2008528617A5 (enExample) 2009-01-29
JP5371246B2 JP5371246B2 (ja) 2013-12-18

Family

ID=36741085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007553278A Expired - Fee Related JP5371246B2 (ja) 2005-01-27 2006-01-27 転移した腫瘍の治療
JP2013129277A Withdrawn JP2013177464A (ja) 2005-01-27 2013-06-20 転移した腫瘍の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013129277A Withdrawn JP2013177464A (ja) 2005-01-27 2013-06-20 転移した腫瘍の治療

Country Status (22)

Country Link
US (2) US20060183750A1 (enExample)
EP (2) EP1845990B1 (enExample)
JP (2) JP5371246B2 (enExample)
KR (1) KR101387985B1 (enExample)
CN (1) CN103893181A (enExample)
AT (1) ATE526025T1 (enExample)
AU (1) AU2006208012B2 (enExample)
BR (1) BRPI0607285A2 (enExample)
CA (1) CA2596084A1 (enExample)
CY (1) CY1112570T1 (enExample)
DK (1) DK1845990T3 (enExample)
ES (2) ES2374570T3 (enExample)
IL (1) IL184866A0 (enExample)
MA (1) MA29266B1 (enExample)
MX (1) MX2007009099A (enExample)
NO (1) NO20074360L (enExample)
PL (2) PL2301546T3 (enExample)
PT (2) PT2301546E (enExample)
SG (1) SG173317A1 (enExample)
SI (1) SI2301546T1 (enExample)
TN (1) TNSN07294A1 (enExample)
WO (1) WO2006081445A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
NZ524717A (en) 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
PT1885187E (pt) * 2005-05-13 2013-12-16 Novartis Ag Métodos para o tratamento de cancro resistente a fármacos
RU2425041C2 (ru) * 2005-05-23 2011-07-27 Новартис Аг Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
TR201819653T4 (tr) * 2010-04-16 2019-01-21 Novartis Ag Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik.
KR20140023358A (ko) * 2011-05-19 2014-02-26 노파르티스 아게 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CN109689649B (zh) * 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
EP0627940B1 (en) * 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
BR9711805A (pt) 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
EP1226136B1 (en) 1999-10-19 2004-12-29 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1351946A2 (en) * 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
NZ524717A (en) * 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
KR101224410B1 (ko) * 2003-11-07 2013-01-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 퀴놀리논 화합물을 합성하는 방법
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
US20060261307A1 (en) * 2005-05-18 2006-11-23 Black D J Water Activated Organic Scavenger
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Similar Documents

Publication Publication Date Title
JP2013507415A5 (enExample)
JP2008528671A5 (enExample)
JP2012525393A5 (enExample)
JP2011518202A5 (enExample)
JP2013519632A5 (enExample)
JP2006143751A5 (enExample)
JP2009536191A5 (enExample)
JP2010077141A5 (enExample)
JP2005525345A5 (enExample)
JP2013513613A5 (enExample)
JP2015508103A5 (enExample)
JP2008528617A5 (enExample)
JP2015536986A5 (enExample)
JP2013540114A5 (enExample)
JP2005511556A5 (enExample)
JP2014505107A5 (enExample)
JP2015503596A5 (enExample)
JP2007523177A5 (enExample)
CN101484443B (zh) 放射线治疗增强剂
WO2023114871A1 (en) Use of combination therapy for treating cancer
CA2596084A1 (en) Treatment of metastasized tumors with quinolinone benzimidazole compounds
JP2007518815A5 (enExample)
JP2009502777A5 (enExample)
NZ530572A (en) Combinations comprising bisphosphonate and epothilones, and pharmaceutical uses thereof
JP2008525493A5 (enExample)